The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Highlights from ASH 2020: BiTEs in myeloma
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, highlights the exciting new findings presented at ASH 2020. He focuses on the use of bispecific antibodies in myeloma, where multiple agents are being evaluated in clinical trials and yielding impressive response rates in the patient cohorts. Teclistamab in particular has shown extremely high responses in a heavily pretreated population. Bispecific antibodies also have a very encouraging safety profile and provide new treatment options for patients who have failed their previous lines of therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
